Literature DB >> 18808170

The inhibitory potencies of monoclonal antibodies to the macrophage adhesion molecule sialoadhesin are greatly increased following PEGylation.

Julie Ducreux1, Rita Vanbever, Paul R Crocker.   

Abstract

PEGylation of antibodies is known to increase their half-life in systemic circulation, but nothing is known regarding whether PEGylation can improve the inhibitory potency of antibodies against target receptors. In this paper, we have examined this question using antibodies directed to Sialoadhesin (Sn), a macrophage-restricted adhesion molecule that mediates sialic acid dependent binding to different cells. Anti-Sn monoclonal antibodies (mAbs), SER-4 and 3D6, were conjugated to PEG 5 kDa or and PEG 20 kDa, resulting in the incorporation of up to 3 molecules of PEG per mAb molecule. Following purification of PEGylated mAbs by anion exchange chromatography, it was shown that PEGylation had little or no effect on antigen binding activity but led to a dramatic increase in inhibitory potency that was proportional to both the size of the PEG and the degree of derivatization. Thus, PEGylation of antibodies directed to cell surface receptors could be a powerful approach to improve the therapeutic efficacy of antibodies, not only by increasing their half-life in vivo, but also by increasing their inhibitory potency for blocking receptor-ligand interactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18808170      PMCID: PMC2730630          DOI: 10.1021/bc800259z

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  20 in total

1.  Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.

Authors:  D Nath; A Hartnell; L Happerfield; D W Miles; J Burchell; J Taylor-Papadimitriou; P R Crocker
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Ultrastructural localisation of sialoadhesin (siglec-1) on macrophages in rodent lymphoid tissues.

Authors:  I L Schadee-Eestermans; E C Hoefsmit; M van de Ende; P R Crocker; T K van den Berg; C D Dijkstra
Journal:  Immunobiology       Date:  2000-11       Impact factor: 3.144

4.  Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations.

Authors:  A Hartnell; J Steel; H Turley; M Jones; D G Jackson; P R Crocker
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 5.  PEGylation, successful approach to drug delivery.

Authors:  Francesco M Veronese; Gianfranco Pasut
Journal:  Drug Discov Today       Date:  2005-11-01       Impact factor: 7.851

6.  VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice.

Authors:  A Soriano; A Salas; A Salas; M Sans; M Gironella; M Elena; D C Anderson; J M Piqué; J Panés
Journal:  Lab Invest       Date:  2000-10       Impact factor: 5.662

7.  Attenuated demyelination in the absence of the macrophage-restricted adhesion molecule sialoadhesin (Siglec-1) in mice heterozygously deficient in P0.

Authors:  Igor Kobsar; Cornelia Oetke; Antje Kroner; Carsten Wessig; Paul Crocker; Rudolf Martini
Journal:  Mol Cell Neurosci       Date:  2006-02-03       Impact factor: 4.314

Review 8.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

Review 9.  PEGylated antibodies and antibody fragments for improved therapy: a review.

Authors:  Andrew P Chapman
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

10.  Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages.

Authors:  P R Crocker; S Gordon
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.